Khaled Elshazly: Can We Stop Chemotherapy-Induced Thrombocytopenia from Delaying Treatment?
Khaled Elshazly, Head of Oncology Clinical Pharmacists and the IV Admixture Unit at Agouza Hospital, shared a LinkedIn post about a recent article by Hanny Al-Samkari et al., published in The New England Journal of Medicine:
”Breakthrough in cancer care: Can we stop chemotherapy-induced thrombocytopenia (CIT) from delaying treatment?
A major challenge in oncology is having to reduce or delay life-saving chemotherapy because it destroys platelet-producing bone marrow cells. But a new global Phase 3 clinical trial just published in the New England Journal of Medicine (NEJM) offers a highly effective solution.
Led by investigators at Mass General Brigham, the trial evaluated Romiplostim vs. Placebo for Chemotherapy-Induced Thrombocytopenia (CIT).
Here are the game-changing results:
- The Trial: 165 patients (109 on romiplostim, 56 on placebo).
- The Impact: Patients taking romiplostim had a >10-fold lower odds of needing a chemotherapy dose reduction due to CIT.
- Efficacy: A remarkable 84% of patients in the romiplostim group required no chemotherapy dose modifications at all, compared to just 36% in the placebo group.
- Safety: The drug was well-tolerated. While overall adverse events were slightly higher in the treatment group, this primarily reflected the fact that these patients were successfully able to receive higher, un-reduced doses of their multi-agent chemotherapy.
Why this matters:
Romiplostim effectively boosts the bone marrow’s resilience, allowing patients to maintain their critical platelet counts. This means fewer treatment interruptions, optimal chemotherapy dosing, and better overall outcomes for cancer patients.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al-Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 20, 2026, 16:31Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
-
Mar 20, 2026, 16:28Breanna Beers: A Remarkable Case of ‘Generation Skipping’ Marfan Syndrome
-
Mar 20, 2026, 16:26Results from The HUNT Study on The Role of Plasma miR-145-5p Levels in Cancer-Associated VTE – JTH
-
Mar 20, 2026, 16:23Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
-
Mar 20, 2026, 16:22Welcoming Samer Al Hadidi to the Blood Cancers Team – UT Southwestern Simmons Cancer Center
-
Mar 20, 2026, 16:21Maxime Dely: The Lifesaving Power of Plasma Donations
-
Mar 20, 2026, 16:20Yves Bikorimana: Hemolysis – Why It Ruins Laboratory Results
-
Mar 20, 2026, 16:19Simon Senanu: G6PD Deficiency Testing – What the Lab Must Get Right
-
Mar 20, 2026, 15:50Rithwic Mani: Platelet-to-Lymphocyte Ratio as A Simple and Cost-Effective Prognostic Biomarker in Stroke